For these reasons, the use of HDAC inhibitors in the management of gliomas is studied in clinical trials using pan-inhibitors: valproic acid (NCT00302159), panobinostat (NCT00859222) or vorinostat (NCT01236560) as adjuvant therapy to radiotherapy and/or chemotherapy. Here, HDAC9 is linked to glioma.